Bariatric Surgery Significantly Outperform GLP-1 Medications for Weight Loss

The recent findings from a study presented at the American Society for Metabolic and Bariatric Surgery's 2025 Annual Scientific Meeting reveal a stark contrast in weight loss results between bariatric surgery and popular GLP-1 medications. According to research conducted by experts from NYU Langone Health and NYC Health + Hospitals, individuals who underwent procedures like sleeve gastrectomy or gastric bypass experienced nearly five times the weight loss of patients using GLP-1 receptor agonists such as semaglutide and tirzepatide.

Over a two-year period, bariatric surgery patients lost an average of 58 pounds, while those on GLP-1 medications managed only about 12 pounds. This equates to a total weight loss of approximately 24% for surgery recipients compared to just 4.7% for medication users. Even among those who remained committed to GLP-1 therapy for a full year, average weight loss only reached around 7%, which still falls short of the outcomes tied to surgical options.

Discrepancy in Weight Loss Results

Lead researcher Dr. Avery Brown points out the discrepancy between clinical trials, which show a weight loss of 15% to 21% for GLP-1s, and real-world results that appear significantly lower. "Our study indicates that many patients struggle to maintain treatment, with nearly 70% discontinuing their medication within a year," Brown notes. This mismatch raises significant questions about the effectiveness of GLP-1s when viewed outside controlled clinical settings. The disparity between trial outcomes and real-world effectiveness can erode trust in medication-based solutions, pushing patients toward more invasive treatments like surgical options.

Methodology and Comparison of Treatments

The investigative team gathered data from electronic medical records of patients treated between 2018 and 2024 at the associated health systems. All subjects were classified with a body mass index (BMI) of at least 35 and either opted for bariatric surgery or received prescriptions for GLP-1 medications. The researchers adjusted for factors like age, BMI, and existing co-morbidities to create a fair comparison across both cohorts of 51,085 patients.

This rigorous methodology ensures the findings hold weight, but it also shines a light on a larger issue: many patients face challenges in choosing between treatments. Navigating the decision between taking medication or undergoing surgery can be daunting, especially when both options come with their unique sets of risks and rewards. Future research efforts aim to fine-tune treatment approaches, examining how healthcare providers can enhance outcomes for GLP-1 users, accurately identify patients suited for each treatment, and assess the implications of out-of-pocket costs on treatment success, as highlighted by senior author Dr. Karan R. Chhabra.

Understanding Medication Usage and Challenges

While GLP-1 drugs have gained traction—with around 12% of Americans having tried them at some point and about 6% currently using them—adherence remains a significant hurdle. Studies indicate that over half of patients with obesity discontinue GLP-1 therapy within the first year, and this rate climbs to more than 72% by the two-year mark. This pattern suggests systemic issues, possibly indicating that many patients struggle with side effects or don't see the results they anticipated.

Conversely, bariatric surgery usage remains limited despite its efficacy. The American Society for Metabolic and Bariatric Surgery reports that only about 1% of eligible individuals undergo surgical intervention, even though more than 270,000 procedures were conducted in 2023 alone. Dr. Ann M. Rogers, president of the ASMBS, emphasizes the effectiveness and durability of surgical weight loss, suggesting that patients who do not achieve satisfactory weight loss from medications should consider bariatric surgery as a viable option or even in conjunction with pharmacological treatment. This highlights that despite the promising results of surgery, awareness and access remain significant barriers for many.

The Bigger Picture of Obesity Treatment

The CDC reports that obesity afflicts 40.3% of adults in the United States, with severe obesity affecting 9.4%. Excess weight has serious ramifications, including exacerbating chronic conditions like cardiovascular diseases and diabetes, but too often, patients and healthcare providers don’t engage in discussions about the most effective treatment strategies. As such, the implications of these findings are critical in informing treatment conversations. If you're working in this space, understanding the stark differences in outcomes between medications and surgery can inform discussions with patients about what to expect.

Future Implications and Conclusion

The study not only highlights the differences in effectiveness between surgery and medications but also reiterates the essential role of patient education and realistic expectations regarding weight loss outcomes. The gulf between the promise of GLP-1 therapies and their practical performance suggests that healthcare providers may need to adjust their treatment paradigms. They might prioritize patient consultation that emphasizes not just medication adherence but also the potential merits of surgical solutions. This highlights an evolving conversation within obesity treatment, where understanding patient motivation and expectations could be key in improving adherence and outcomes.